One other item for the cc, I noticed, BP knows thi
Post# of 155372
(Total Views: 1079)
Posted On: 08/10/2019 3:53:20 PM
One other item for the cc, I noticed, BP knows this as well. Once a week therapy, both doctors commented on this and gave stats, see below. Sacha a survey and Lalezari, who has direct experience, gave his gut about percent had solid interest in once a week therapy. Add the fact there are little side effects and it is a killer combo, very easy sale.
Leronlimab monotherapy could take away 20% of the market, 1.1M in US with HIV, US is making a push to have everyone on drugs, 70% with r5, that is 5B yearly market. In my opinion, Gilead will offer big bucks if leronlimab monotherapy looks inevitable.
Once a week therapy has a huge huge market just waiting for the right drug. Lalezari said the reality of what is involved with painful monthly injection at doctors office is settling in.
At 6min, Sacha said 25% of high risk men surveyed can't adhere to PrEP because the inability to take the daily regimen. Leronlimab would fill a major gap in PrEP
At 13:20 min, Lalezari, could enroll all patients at his site in study, lots of interest because of less side effects, pill fatigue, or chaotic lifestyles, not all patients but a solid 10-15% of the population. Patients who do well on leronlimab monotherapy, love it. It has been a life changer for some patients. No concern around injection site reactions. I don't see any issue, at all really, with safety or toxicity.
Leronlimab monotherapy could take away 20% of the market, 1.1M in US with HIV, US is making a push to have everyone on drugs, 70% with r5, that is 5B yearly market. In my opinion, Gilead will offer big bucks if leronlimab monotherapy looks inevitable.
Once a week therapy has a huge huge market just waiting for the right drug. Lalezari said the reality of what is involved with painful monthly injection at doctors office is settling in.
At 6min, Sacha said 25% of high risk men surveyed can't adhere to PrEP because the inability to take the daily regimen. Leronlimab would fill a major gap in PrEP
At 13:20 min, Lalezari, could enroll all patients at his site in study, lots of interest because of less side effects, pill fatigue, or chaotic lifestyles, not all patients but a solid 10-15% of the population. Patients who do well on leronlimab monotherapy, love it. It has been a life changer for some patients. No concern around injection site reactions. I don't see any issue, at all really, with safety or toxicity.
(1)
(0)